Cancer combo shows promise in myeloma maintenance trial
NCT ID NCT03622775
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 38 times
Summary
This study looked at whether combining two drugs, daratumumab and pomalidomide, could help keep multiple myeloma from coming back in patients who had already relapsed after a stem cell transplant. The 13 participants received the drug combination as maintenance therapy after a second transplant. The trial was stopped early, but researchers measured how many patients achieved complete remission and how long they lived without the cancer progressing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.